The governor visited Estacada High School Wednesday afternoon, with students and teachers weighing in on the progress made ...

A clinical trial in China testing ICP-538, a treatment candidate for MS and other autoimmune diseases, has dosed its first healthy volunteer.

A protein already targeted by FDA-approved cancer drugs may also help the body fight influenza, according to new research from The Jackson Laboratory (JAX). Published in Cell Reports, the study found ...

Universal month-3 NGF MRD negativity (10⁻⁵) followed short-course VRd or daratumumab-based induction and single-infusion YK-hBCMA BB-002, despite high-risk biology and frailty representation. Depth of ...

This new type of immunotherapy shows promise for treating different cancers including prostate cancer, leukaemia and lung ...

Backed by more than a dozen investors, the biotech startup will use the funding to further a Phase 1 trial of its lead program CBX-250.

Cancer-fighting T cells do not simply "run out of energy." They are molecularly reprogrammed. For years, mitochondrial dysfunction has been recognized as a hallmark of exhausted T cells in tumors. Yet ...

UCSF scientists found a precise way to turn on cancer-fighting immune cells inside the body. This more potent form of CAR-T ...

The world is experiencing a hidden epidemic with kidney disease. More than 850 million people worldwide have some form of ...

The Citizens Life Sciences Conference 2026 March 11, 2026 1:40 PM EDTCompany ParticipantsSteven Harr - President, CEO ...

In stable MS patients, stopping Ocrevus does not seem to increase the risk of disease activity or disability progression for ...

The bispecific T-cell engager talquetamab (Talvey) has some distinct adverse events (AEs) compared with drugs of the same class that target B-cell maturation antigen (BCMA) in mul ...